Vaxcyte, Inc. (NASDAQ: PCVX) is a Healthcare company (Biotechnology) with a market capitalization of $9.4B. The Maz Rating grades it against the other companies in its sector.
Vaxcyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $59.40, Vaxcyte, Inc. trades at 3.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -42.0%, return on invested capital of -45.4% and a free cash flow yield of -13.6%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 4.56. Over the past 52 weeks the share price ranged from $42.40 to $90.75, with a beta of 1.29.
Vaxcyte, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 11 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.